ReviewNature reviews. Disease primers2016
Irritable bowel syndrome.
Review in Nature reviews. Disease primers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 496 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of a Yoga Intervention on Chronic Abdominal Pain, and Associations With the Metagenome and Metabolome in Participants With IBS
A Pilot Study of Auricular Microstimulation to Determine if it Improves Vagal Modulation
The Efficacy and Safety of CMTS4520 for Chronic Diarrhoea in Adults： A Randomized, Double-Blind, Placebo-Controlled Trial.
The Efficacy and Safety of CMTS4520-Assisted Washed Microbiota Transplantation for Chronic Diarrhoea in Adults： a Randomized, Double-Blind, Placebo-Controlled Trial.
Who cites it
496 citing papers in PubMed, 10 syntheses or guidelines pooled it, 964 citations in OpenAlex.
- Pooled it
- Mapping research trends in irritable bowel syndrome and the gut microbiome: a cross-database bibliometric analysis.Frontiers in microbiology · 2026Pooled it
- Manifestations of the oral mucosa and salivary glands in irritable bowel syndrome and microscopic colitis - A systematic review.Acta odontologica Scandinavica · 2025Pooled it
- Efficacy and safety of Chinese botanical drug Si Shen Wan in irritable bowel syndrome: a meta-analysis and trial sequential analysis of randomized controlled trials.Frontiers in pharmacology · 2025Pooled it
- Pooled it
- Global Prevalence of Fecal Incontinence in Community-Dwelling Adults: A Systematic Review and Meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024Pooled it
- Major depressive disorder and the risk of irritable bowel syndrome: A Mendelian randomization study.Molecular genetics & genomic medicine · 2024Pooled it
- Symptom effects and central mechanism of acupuncture in patients with functional gastrointestinal disorders: a systematic review based on fMRI studies.BMC gastroenterology · 2024Pooled it
- Causality of genetically determined blood metabolites on irritable bowel syndrome: A Mendelian randomization study.PloS one · 2024Pooled it
- Efficacy of moxibustion in diarrhea-predominant irritable bowel syndrome model rats: a systematic review and meta-analysis.Frontiers in bioengineering and biotechnology · 2023Pooled it
- Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model.Gut microbes · 2025Trial
- A Randomized Waitlist-Controlled Trial of a Positive Psychology Intervention for Irritable Bowel Syndrome: The WISH Proof-of-Concept Trial.Neurogastroenterology and motility · 2025Trial
- Elevated Fecal Biomarkers of Colo-Rectal Epithelial Cell Activity in Irritable Bowel Syndrome.Neurogastroenterology and motility · 2025Trial
- Tenapanor Improves Abdominal Symptoms Irrespective of Changes in Complete Spontaneous Bowel Movement Frequency in Adults with Irritable Bowel Syndrome with Constipation.Digestive diseases (Basel, Switzerland) · 2025Trial
- Fecal microbiota transplantation influences microbiota without connection to symptom relief in irritable bowel syndrome patients.NPJ biofilms and microbiomes · 2024Trial
- Efficacy of acupuncture in refractory irritable bowel syndrome patients: a randomized controlled trial.Frontiers of medicine · 2024Trial
- Trial
- Efficacy of a Synbiotic ContainingGut and liver · 2023Trial
- Progress in pain mechanisms and management.Signal transduction and targeted therapy · 2026Review
- Lactiplantibacillus Plantarum CKDB008 and Lacticaseibacillus Rhamnosus LDTM7511 Attenuate Visceral Hypersensitivity and Suppress Serum IgE in an Acetic Acid-Induced IBS-Like Rat Model.Probiotics and antimicrobial proteins · 2026Article
436 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 9 institutions in 7 countries.
Funding
Abstract
Irritable bowel syndrome (IBS) is a functional gastrointestinal disease with a high population prevalence. The disorder can be debilitating in some patients, whereas others may have mild or moderate symptoms. The most important single risk factors are female sex, younger age and preceding gastrointestinal infections. Clinical symptoms of IBS include abdominal pain or discomfort, stool irregularities and bloating, as well as other somatic, visceral and psychiatric comorbidities. Currently, the diagnosis of IBS is based on symptoms and the exclusion of other organic diseases, and therapy includes drug treatment of the predominant symptoms, nutrition and psychotherapy. Although the underlying pathogenesis is far from understood, aetiological factors include increased epithelial hyperpermeability, dysbiosis, inflammation, visceral hypersensitivity, epigenetics and genetics, and altered brain-gut interactions. IBS considerably affects quality of life and imposes a profound burden on patients, physicians and the health-care system. The past decade has seen remarkable progress in our understanding of functional bowel disorders such as IBS that will be summarized in this Primer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.